- Home
- MFIN vs WHWK Comparison
MFIN vs WHWK Comparison
Compare MFIN & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MFIN | WHWK |
|---|---|---|
| Founded | 1995 | 2007 |
| Country | United States | United States |
| Employees | 179 | 23 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 229.0M | 187.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | MFIN | WHWK |
|---|---|---|
| Price | $10.94 | $4.76 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $12.00 | $7.50 |
| AVG Volume (30 Days) | 40.4K | ★ 413.9K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | ★ 5.18% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.02 | N/A |
| P/E Ratio | $6.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.85 | $1.57 |
| 52 Week High | $11.05 | $5.50 |
Technical Indicators
Market Signals| Indicator | MFIN | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 67.98 | 69.25 |
| Support Level | $9.20 | $3.70 |
| Resistance Level | N/A | $4.82 |
| Average True Range (ATR) | 0.32 | 0.25 |
| MACD | 0.11 | 0.09 |
| Stochastic Oscillator | 87.19 | 97.74 |
Price Performance
Historical ComparisonAbout MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The four operating segments are, (1) recreation, (2) home improvement, (3) commercial and (4) taxi medallion The company generates maximum revenue from the Recreation segment. The company's geographic Concentrations are in united states diversified in California, Wisconsin, New York, Texas and others.
About WHWK Whitehawk Therapeutics Inc.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.